CL2008000507A1 - Preparacion regioespecifica de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroxi metil)-2- metil propionico, protegido con isopropilidencetal; y composicion farmaceutica que comprende a dicho compuesto. - Google Patents

Preparacion regioespecifica de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroxi metil)-2- metil propionico, protegido con isopropilidencetal; y composicion farmaceutica que comprende a dicho compuesto.

Info

Publication number: CL2008000507A1
Authority: CL; Chile
Prior art keywords: hydroxy; regapespecific; isopropilidencetal; rapamycin; propionic
Prior art date: 2004-04-14

Application number

CL200800507A

Other languages

English (en)

Inventor

Jianxin Cai Ping Ruppen Mar Gu

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-14

Filing date

2008-02-19

Publication date

2008-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-19 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-07-04 Publication of CL2008000507A1 publication Critical patent/CL2008000507A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Hematology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Enzymes And Modification Thereof (AREA)

CL200800507A 2004-04-14 2008-02-19 Preparacion regioespecifica de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroxi metil)-2- metil propionico, protegido con isopropilidencetal; y composicion farmaceutica que comprende a dicho compuesto. CL2008000507A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US56192604P	2004-04-14	2004-04-14

Publications (1)

Publication Number	Publication Date
CL2008000507A1 true CL2008000507A1 (es)	2008-07-04

Family

ID=34965235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800507A CL2008000507A1 (es)	2004-04-14	2008-02-19	Preparacion regioespecifica de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroxi metil)-2- metil propionico, protegido con isopropilidencetal; y composicion farmaceutica que comprende a dicho compuesto.

Country Status (23)

Country	Link
US (1)	US7268144B2 (es)
EP (1)	EP1737869A1 (es)
JP (1)	JP4224115B2 (es)
KR (1)	KR20070015544A (es)
CN (1)	CN1942476A (es)
AR (1)	AR049019A1 (es)
AU (1)	AU2005238431A1 (es)
BR (1)	BRPI0509852A (es)
CA (1)	CA2562952A1 (es)
CL (1)	CL2008000507A1 (es)
CR (1)	CR8646A (es)
EC (1)	ECSP066927A (es)
GT (1)	GT200500085A (es)
IL (1)	IL178315A0 (es)
MX (1)	MXPA06011881A (es)
NO (1)	NO20065090L (es)
PA (1)	PA8629901A1 (es)
PE (1)	PE20060253A1 (es)
RU (1)	RU2387657C2 (es)
SG (1)	SG152234A1 (es)
TW (1)	TW200536542A (es)
UA (1)	UA87492C2 (es)
WO (1)	WO2005105811A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ537829A (en)	2002-07-30	2006-09-29	Wyeth Corp	Parenteral formulations containing a rapamycin hydroxyester
AU2005238432A1 (en) *	2004-04-14	2005-11-10	Wyeth	Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
CA2562164A1 (en) *	2004-04-27	2005-11-10	Wyeth	Labeling of rapamycin using rapamycin-specific methylases
MX2007001676A (es) *	2004-08-10	2007-04-12	Wyeth Corp	Derivados de 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionico y metodos para hacer los mismos.
CA2595766A1 (en) *	2005-02-09	2006-08-17	Wyeth	Cci-779 polymorph and use thereof
WO2007056175A2 (en) *	2005-11-04	2007-05-18	Wyeth	41-methoxy isotope labeled rapamycin 42-ester
US7622578B2 (en) *	2005-12-07	2009-11-24	Wyeth	Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
AR058282A1 (es) *	2005-12-07	2008-01-30	Wyeth Corp	Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
BRPI0619592A2 (pt) *	2005-12-07	2016-09-06	Wyeth Corp	métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
MX2008011458A (es) *	2006-03-07	2008-09-24	Wyeth Corp	Procedimiento para preparar conjugados de polietilenglicol solubles en agua de inmunosupresores de macrolidos.
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
TW200845960A (en) *	2007-04-05	2008-12-01	Wyeth Corp	Wortmannin-rapalog conjugate and uses thereof
US20090253733A1 (en) *	2008-04-02	2009-10-08	Biointeractions, Ltd.	Rapamycin carbonate esters
US20110098241A1 (en) *	2008-04-14	2011-04-28	Poniard Pharmaceuticals, Inc.	Rapamycin analogs as anti-cancer agents
CN101676291B (zh) *	2008-09-18	2012-05-09	上海海和药物研究开发有限公司	一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EP2365802B1 (en)	2008-11-11	2017-08-02	The Board of Regents,The University of Texas System	Microcapsules of rapamycin and use for treating cancer
IT1394309B1 (it) *	2009-05-22	2012-06-06	Poli Ind Chimica Spa	Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
MX2013011412A (es) *	2011-04-01	2014-04-30	Sandoz Ag	Acilacion regioselectiva de rapamicina en la posicion c-42.
US10751450B2 (en)	2012-06-08	2020-08-25	Biotronik Ag	Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
US9408884B2 (en) *	2012-06-08	2016-08-09	Biotronik Ag	Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
EP2968281B1 (en)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
ES2897473T3 (es) *	2013-03-15	2022-03-01	Biosensors Int Group Ltd	Purificación de derivados de la rapamicina
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
EP4014967A1 (en)	2016-04-29	2022-06-22	Icahn School of Medicine at Mount Sinai	Targeting the innate immunesystem to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
US11225487B2 (en)	2017-02-17	2022-01-18	Trevena, Inc.	7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same
EP3848065B1 (en)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
EP3713547A4 (en) *	2017-11-20	2023-07-19	Icahn School of Medicine at Mount Sinai	INHIBITION OF TRAINED IMMUNITY WITH A THERAPEUTIC NANOBIOLOGICAL COMPOSITION
EP3880266B1 (en)	2018-11-14	2025-05-07	Lutonix, Inc.	Medical device with drug-eluting coating on modified device surface
WO2020209828A1 (en)	2019-04-08	2020-10-15	Bard Peripheral Vascular, Inc.	Medical device with drug-eluting coating on modified device surface
EP4259100A1 (en) *	2020-12-14	2023-10-18	Biotronik Ag	Materials and methods for treating viral and other medicinal conditions
CN118459539B (zh)	2021-03-19	2026-01-06	生物治疗探索股份有限公司	用于调节训练免疫的化合物及其使用方法
WO2023070605A1 (en) *	2021-10-29	2023-05-04	Trevena, Inc.	Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
CN118027062B (zh) *	2023-11-03	2025-02-14	沈阳药科大学	一种雷帕霉素前药及其纳米制剂的制备和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4316885A (en)	1980-08-25	1982-02-23	Ayerst, Mckenna And Harrison, Inc.	Acyl derivatives of rapamycin
US4650803A (en)	1985-12-06	1987-03-17	University Of Kansas	Prodrugs of rapamycin
US5210030A (en) *	1990-06-25	1993-05-11	Merck & Co., Inc.	Process for selectively acylating immunomycin
PT98990A (pt) *	1990-09-19	1992-08-31	American Home Prod	Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en)	1990-10-16	1993-08-03	American Home Products Corporation	Rapamycin alkoxyesters
US5100883A (en)	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en)	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
US5118677A (en)	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
US5260300A (en)	1992-11-19	1993-11-09	American Home Products Corporation	Rapamycin carbonate esters as immuno-suppressant agents
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5780462A (en)	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
TWI256395B (en) *	1999-09-29	2006-06-11	Wyeth Corp	Regioselective synthesis of rapamycin derivatives
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
EP1319008B1 (en)	2000-09-19	2008-10-15	Wyeth	Water soluble rapamycin esters
NZ537829A (en)	2002-07-30	2006-09-29	Wyeth Corp	Parenteral formulations containing a rapamycin hydroxyester
KR20060057605A (ko)	2003-08-07	2006-05-26	와이어쓰	Ｃｃｉ-779의 위치선택적 합성 방법
RU2345999C2 (ru)	2003-09-03	2009-02-10	Уайт	Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
JP2007517879A (ja) *	2004-01-08	2007-07-05	ワイス	Ｃｃｉ−７７９経口投与用の直接圧縮可能な医薬組成物

2005
- 2005-04-12 JP JP2007508442A patent/JP4224115B2/ja not_active Expired - Fee Related
- 2005-04-12 MX MXPA06011881A patent/MXPA06011881A/es active IP Right Grant
- 2005-04-12 CN CNA2005800112769A patent/CN1942476A/zh active Pending
- 2005-04-12 EP EP05733853A patent/EP1737869A1/en not_active Withdrawn
- 2005-04-12 RU RU2006134014/04A patent/RU2387657C2/ru not_active IP Right Cessation
- 2005-04-12 US US11/103,799 patent/US7268144B2/en not_active Expired - Fee Related
- 2005-04-12 CA CA002562952A patent/CA2562952A1/en not_active Abandoned
- 2005-04-12 AU AU2005238431A patent/AU2005238431A1/en not_active Abandoned
- 2005-04-12 KR KR1020067021378A patent/KR20070015544A/ko not_active Ceased
- 2005-04-12 WO PCT/US2005/012266 patent/WO2005105811A1/en not_active Ceased
- 2005-04-12 BR BRPI0509852-1A patent/BRPI0509852A/pt not_active IP Right Cessation
- 2005-04-12 SG SG200902515-6A patent/SG152234A1/en unknown
- 2005-04-13 PA PA20058629901A patent/PA8629901A1/es unknown
- 2005-04-13 TW TW094111640A patent/TW200536542A/zh unknown
- 2005-04-13 GT GT200500085A patent/GT200500085A/es unknown
- 2005-04-13 PE PE2005000409A patent/PE20060253A1/es not_active Application Discontinuation
- 2005-04-13 AR ARP050101447A patent/AR049019A1/es unknown
- 2005-12-04 UA UAA200610949A patent/UA87492C2/ru unknown
2006
- 2006-09-21 CR CR8646A patent/CR8646A/es not_active Application Discontinuation
- 2006-09-26 IL IL178315A patent/IL178315A0/en unknown
- 2006-10-16 EC EC2006006927A patent/ECSP066927A/es unknown
- 2006-11-03 NO NO20065090A patent/NO20065090L/no not_active Application Discontinuation
2008
- 2008-02-19 CL CL200800507A patent/CL2008000507A1/es unknown

Also Published As

Publication number	Publication date
TW200536542A (en)	2005-11-16
US20050234234A1 (en)	2005-10-20
KR20070015544A (ko)	2007-02-05
RU2006134014A (ru)	2008-05-20
RU2387657C2 (ru)	2010-04-27
JP2007532134A (ja)	2007-11-15
WO2005105811A1 (en)	2005-11-10
GT200500085A (es)	2005-11-03
AU2005238431A1 (en)	2005-11-10
IL178315A0 (en)	2007-02-11
UA87492C2 (en)	2009-07-27
EP1737869A1 (en)	2007-01-03
ECSP066927A (es)	2006-12-20
AR049019A1 (es)	2006-06-21
NO20065090L (no)	2006-11-13
SG152234A1 (en)	2009-05-29
CR8646A (es)	2007-08-28
CN1942476A (zh)	2007-04-04
MXPA06011881A (es)	2006-12-14
JP4224115B2 (ja)	2009-02-12
PA8629901A1 (es)	2006-06-02
US7268144B2 (en)	2007-09-11
BRPI0509852A (pt)	2007-10-23
CA2562952A1 (en)	2005-11-10
PE20060253A1 (es)	2006-03-30

Publication	Publication Date	Title
CL2008000507A1 (es)	2008-07-04	Preparacion regioespecifica de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroxi metil)-2- metil propionico, protegido con isopropilidencetal; y composicion farmaceutica que comprende a dicho compuesto.
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
EP1841761A4 (en)	2008-10-29	Fumagillol derivatives or processes for the preparation of fumagillol derivatives, and pharmaceutical compositions containing them
BRPI0818804A2 (pt)	2015-04-22	Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0609802A2 (pt)	2017-05-02	composto, composição farmacêutica e uso de um composto
EP1988951B8 (en)	2019-06-12	Controlled flashback for vascular access devices
BRPI0716698A2 (pt)	2014-02-25	Composto, composição farmacêutica e uso de um composto
PL2076244T3 (pl)	2017-05-31	Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie
CL2007002916A1 (es)	2008-04-18	Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BRPI0819696A2 (pt)	2015-06-16	Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
CL2007002377A1 (es)	2008-04-04	Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
IL195488A (en)	2017-04-30	Compounds, pharmaceuticals containing them and their uses
IL198119A0 (en)	2009-12-24	Pesticidal composition comprising fenamidone and an insecticide compound
BRPI0809977A2 (pt)	2014-10-07	Uso de um composto, compostos e composição farmacêutica que o contém
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0812942A2 (pt)	2014-12-16	Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt)	2014-10-14	Composto, composição farmacêutica, e, uso de um composto
IL198631A (en)	2016-03-31	Preparations containing 2-pyridylmethylbenzamide and an insecticide compound
BRPI0716660A2 (pt)	2015-02-10	Peça fundida de metal.
CL2007001919A1 (es)	2008-05-16	Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos.
EP2042164A4 (en)	2010-10-13	STABILIZED SOLID PREPARATION
BRPI0614730A2 (pt)	2016-11-01	composto, composição farmacêutica, e, uso de um composto